Vanucizumab 是一种首创的双特异性 IgG1 单克隆抗体，可同时阻断 VEGF-A 和血管生成素-2 (Ang-2) 与其受体相互作用。 Vanucizumab 具有抗血管生成和抗癌作用。

For Powder, reconstitute with sterile, distilled water to a final concentration of 1 mg/ml. Gently shake to solubilize completely. Do not vortex.

本产品仅用作科学研究！

Anti-ANG2 & VEGFA Reference Antibody (Vanucizumab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 96%.

The purity of Anti-ANG2 & VEGFA Reference Antibody (Vanucizumab) is more than 95%, determined by SEC-HPLC.

Vanucizumab bound to ANG2 protein, and then rebounded to secondary antibodies (Anti-Human-IgG-Fc-HRP) , and read OD450. As shown in fig, Vanucizumab bound to in huANG2-His, and the EC50 was 0.288 nM.

Vanucizumab bound to VEGFA protein, and then rebounded to secondary antibodies (Anti-Human-IgG-Fc-HRP) , and read OD450. As shown in fig, Vanucizumab bound to in huVEGFA-His, and the EC50 was 0.009 nM.

Co-incubation of Vanucizumab with VEGF protein, then with the addition of VEGF-NF-AT-HEK293 cells and incubated for 6 hours. Bright-Lite was used to detect the fluorescent signal. As shown in fig, Vanucizumab can neutralize VEGF-165, and the IC50 was 1.075 nM.

-80°C for 2 years under sterile conditions；-20°C for 1 year under sterile conditions；Avoid repeated freeze-thaw cycles.